Fellowships for the Division of Pediatric Hematology-Oncology
History and Mission
At the University of North Carolina, we are proud of our history in Pediatric Hematology-Oncology and excited about our future. Our fellowship program was founded in 1972 and has trained leaders in academics, government, and industry. We are committed to continuing this tradition.
We have a faculty dedicated to achieving all three aspects of our mission: patient care, research, and teaching. The unique strengths of our program include our nationally recognized hemophilia and bleeding disorder program, our affiliation with the UNC Lineberger Cancer Center, our combined Medicine-Pediatrics fellowship, collaborations with the School of Public Health and the Eshelman School of Pharmacy, and our new program in cellular therapy. We are a growing, thriving center committed to training the next generation of leaders in Pediatric Hematology-Oncology.
Fellows generally spend the first year in dedicated clinical rotations, with the the next two years 80% protected for research (clinical, basic or translational). Rotations, which fulfill ABP subspecialty board requirements, include four months on our inpatient general hematology-oncology service, three months in outpatient clinics (general hematology-oncology as well as dedicated sickle cell, hemophilia/thrombophilia, neuro-oncology, bone marrow transplantation, and survivorship clinics), two months of bone marrow transplant, two months with time on transfusion medicine/hemepath/radiation oncology/cytogenetics, and four weeks of vacation. During the second and third years of fellowship, fellows participate in a half-day per week continuity clinic. Weekend call during the research years averages every fourth weekend and there is no more than once-a-week night call.
Medicine-Pediatrics Combined Fellowship
For highly qualified applicants, the UNC Pediatric Hematology-Oncology Program and Medical Hematology-Oncology Program offer a combined training program. This program has trained more dual-boarded subspecialists than any other similar program in the country.
Individuals who are interested in this program should first apply to Pediatric Hematology-Oncology and declare their interest in correspondence with the Program Director.
Our fellows have a rich clinical experience. We see over 100 new cancer patients yearly with a broad range of diagnoses. Our sickle cell and hemophilia clinics each follow several hundred patients. Our multidisciplinary team includes PNPs, RNs, social workers, school teachers, psychologists, recreational therapists, as well as colleagues in other divisions.
We care for a diverse population of patients from a wide variety of backgrounds. Our clinical care embodies the unofficial motto of the UNC Hospital system, “By and For the People of North Carolina,” and care is provided regardless of the family’s financial status.
As part of the top public university/top public medical school in the US, our fellows have unparalleled research opportunities in benign hematology, pharmacology, molecular biology, survivorship, epidemiology, gene therapy, and an exciting new commitment to cellular therapies. Research plans are established early during the first year to allow us to help fellows organize a Scholarship Oversight Committee as required by the ABP. We have had fellows engage in a wide range of research activities involving molecular biology, gene therapy of hemophilia, clinical hemophilia and thrombophilia, cancer epidemiology, survivorship, sickle cell disease, and palliative care.
Fellows participate in a variety of educational activities including our multidisciplinary tumor board, patient case conferences, a journal club, and a pediatric hematology-oncology board review series. Fellows work on their presentation skills both in these forums and through teaching opportunities with the Pediatric Residency program.
All fellowship applications should be completed through ERAS.
Address questions to:
Patrick A. Thompson, MD
Fellowship Program Director
Division of Pediatric Hematology-Oncology
170 Manning Drive 1185A POB
University of North Carolina
Chapel Hill, NC 27599
UNC Global Pediatric Hematology-Oncology
The Program: UNC Project Malawi
- 25-year collaboration between UNC and Malawi Ministry of Health (MOH), established in 1991
- >350 employees in Malawi, 40,000-square foot Tidziwe building and a new Annex building that opened in 2016, both on KCH campus
- Training site for Fogarty, Doris Duke, and Fulbright Fellowships
- Clinical trial site for protocols implemented through numerous multinational NIH-sponsored networks
- Links: Malawi Cancer Consortium, UNC-Project Malawi, UNC IGHID
The Site: Kamuzu Central Hospital (KCH)
- Located in the capital of Malawi – Lilongwe
- 1000-bed public tertiary care hospital. Pediatrics is the largest department at KCH with 250 beds but admits up to 500 children during malaria season.
- National teaching hospital with rotating Malawian medical students and residents
- Pediatric Oncology at KCH is serving a catchment area of around 8 million people (Central and Northern Malawi), and Malawian children from the South are referred to Queen Elizabeth Hospital in Blantyre. We are the only 2 centers treating cancer in the country.
Pediatric Heme-Onc Clinical Activities
- UNC works in collaboration with KCH and Texas Children’s & Baylor College of Medicine Children’s Foundation Malawi.
- With UNC and MOH collaboration, we established a pathology lab in 2011. Weekly telepathology conferences are held between USA and Malawi.
- We have access to chemotherapy and supportive cares, but limited access to pediatric surgery and no access to radiation.
- The most common cancers that we treat at KCH are: Burkitt Lymphoma, Hodgkin Lymphoma, Kaposi Sarcoma, Acute Leukemia, Wilms’ Tumor, Neuroblastoma, Rhabdomyosarcoma, retinoblastoma, and bone sarcomas.
- UNC lab initiated hemoglobin electrophoresis testing in 2014.
Pediatric Heme-Onc Research Activities
- UNC has an ongoing prospective lymphoma study since 2013 and a prospective sickle cell cohort since 2014.
- UNC serves as a site for the multinational NIH-sponsored Burkitt Lymphoma Trial Network.
In the News!
- Striving to save more children with cancer in Malawi. Link: http://unclineberger.org/news/striving-to-improve-survival
- UNC Lineberger Researchers to Develop Comics, App to Educate about Childhood Cancer in Malawi. Link: http://www.med.unc.edu/infdis/malawi/news/unc-lineberger-researchers-to-develop-comics-app-to-educate-about-childhood-cancer-in-malawi
- Translation, psychometric validation, and baseline results of the patient-reported outcomes measurement information system (PROMIS) pediatric measures to assess health-related quality of life of pediatric lymphoma patients in Malawi (In-Press)
- Risk factors and reasons for treatment abandonment among children with lymphoma in Malawi. Pubmed Link: https://www.ncbi.nlm.nih.gov/pubmed/28986643
- Dissecting heterogeneous outcomes for paediatric Burkitt lymphoma in Malawi after anthracycline-based treatment. PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/28714257https://www.ncbi.nlm.nih.gov/pubmed/28714257
- Beyond Endemic Burkitt Lymphoma: Navigating Challenges of Differentiating Childhood Lymphoma Diagnoses Amid Limitations in Pathology Resources in Lilongwe, Malawi. PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/28680947
- Plasma Epstein-Barr virus DNA for pediatric Burkitt lymphoma diagnosis, prognosis and response assessment in Malawi. PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/28268254https://www.ncbi.nlm.nih.gov/pubmed/28268254
- Quantifying bias in survival estimates resulting from loss to follow-up among children with lymphoma in Malawi. PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/27896944
- Hodgkin Lymphoma, HIV, and Epstein-Barr Virus in Malawi: Longitudinal Results from the Kamuzu Central Hospital Lymphoma Study. PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/27781380
- Outcomes for paediatric Burkitt lymphoma treated with anthracycline-based therapy in Malawi. PubMed Link
- Establishing sickle cell diagnosis and characterizing a paediatric sickle cell disease cohort in Malawi. PubMed Link